TimesSquare Capital Managementan equity investment management company, has released its “US Small Cap Growth Strategy” for investors for the fourth quarter of 2025. A copy of the book can be downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) in the fourth quarter compared to a 1.22% return for the Russell 2000 Growth Index. By 2025, the strategy has returned 6.91% (gross) and 5.85% (net) compared to 13.01% for the index. Global Equity markets ended the quarter on a positive note, with Europe leading the way, followed by Emerging Markets. In most markets, large caps outperformed small caps. The trade agreement between the United States and China was extended for an additional year, but global concerns, whether related to tariffs or not, continued. Third-quarter GDP beat expectations, but consumer caution remains amid continued softening of the labor market, which has implications for the Fed’s decision to cut interest rates. Please review the top five Strategy items for details on your key choices for 2025.
In its fourth quarter 2025 investor note, TimesSquare Capital US Small Cap Growth Strategy highlighted stocks like ABIVAX Société Anonyme (NASDAQ:ABVX). ABIVAX Société Anonyme (NASDAQ:ABVX) is a French healthcare biotechnology company focused on developing medicines to treat gastrointestinal diseases. On April 1, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) closed at $114.97 per share. ABIVAX Société Anonyme (NASDAQ:ABVX)’s one-month return was -2.01%, and its shares gained 1,885.66% in the last 52 weeks. ABIVAX Société Anonyme (NASDAQ:ABVX) has a market capitalization of $9.11 billion.
TimesSquare Capital US Small Cap Growth Strategy said the following about ABIVAX Société Anonyme (NASDAQ:ABVX) in its fourth quarter 2025 investor note:
“Our picks among Healthcare stocks are those companies that provide new drugs for unmet needs that command high prices, or specialty service providers. That includes a biopharma developer for gastrointestinal treatments, ABIVAX Société Anonyme (NASDAQ: ABVX). We first bought Abivax over the summer, after it reported strong trial results for its obefazimod treatment to treat ulcerative colitis in a long-lasting way with fewer side effects than current drugs. Towards the end of the year, there was speculation that Abivax was in the process of being acquired by a large pharmaceutical company, and we reduced our position as it rose 58%.
ABIVAX Société Anonyme (NASDAQ:ABVX) is not on our list of the 40 Most Popular Stocks Among Hedge Funds Entering 2026. According to our data, 72 hedge fund portfolios held ABIVAX Société Anonyme (NASDAQ:ABVX) at the end of the fourth quarter, up from 56 previously. While we acknowledge the potential of ABIVAX Société Anonyme (NASDAQ:ABVX) as an investment, we believe certain AI stocks offer greater potential and carry less downside risk. If you’re looking for an extremely overlooked AI stock that will benefit greatly from the Trump-era costs and sea trend, check out our free report best short term AI stock.
